Shopping Cart

Your shopping cart is currently empty

Zanubrutinib

Name: Zanubrutinib
Brand: TargetMol
SKU: T7584
Price: 51 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: BGB-3111) Copy Product Info

😃Good

Synonyms: BGB-3111

Catalog No. T7584 Copy Product Info

Purity: 99.76%

😃Good

Zanubrutinib is an oral, irreversible, highly selective Bruton’s tyrosine kinase (BTK) inhibitor (IC₅₀ = 0.3 nM). This agent is used in research on tumors such as lymphoma and leukemia.

Cas No. 1691249-45-2

Pack Size	Price	USA Stock	Global Stock
1 mg	$51	In Stock	In Stock
2 mg	$77	In Stock	In Stock
5 mg	$133	In Stock	In Stock
10 mg	$238	In Stock	In Stock
25 mg	$455	In Stock	In Stock
50 mg	$679	In Stock	In Stock
100 mg	$936	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$138	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.76%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Zanubrutinib is an oral, irreversible, highly selective Bruton’s tyrosine kinase (BTK) inhibitor (IC₅₀ = 0.3 nM). This agent is used in research on tumors such as lymphoma and leukemia.
Targets & IC50	MOLM-13 cells:5095 nM, HEK293 cells:204.7 nM, BTK:0.3 nM, Ramos cells:1.8 nM, Jurkat cells:3477 nM, Rec1 cells:0.36 nM, TMD8 cells:3.8 nM, OCI-LY1 cells:0.35 nM, Sf9 cells:0.3 nM
In vitro	Methods: Human liver microsomes were incubated with 1 μM zanubrutinib, CYP subtype-specific inhibitors, and NADPH for 30 minutes. CYP enzyme phenotypes were analyzed using chemically-inhibited assays. Results: Ketoconazole (a CYP3A inhibitor) significantly inhibited zanubrutinib metabolism, indicating CYP3A as the primary metabolic enzyme. [1] Methods: Lymphoma cell lines Raji, EHEB, JEKO-1, and CD19 CAR-T cells (derived from 7 lymphoma patients) were treated with a concentration gradient of Zanubrutinib (0, 1, 15 μM) for 24 and 48 hours. Cell proliferation inhibition was assessed using the CCK-8 assay. Results: Zanubrutinib exhibited dose-dependent inhibition of proliferation in both lymphoma cells and CAR-T cells. At the low concentration of 1 μM, CAR-T cell inhibition was minimal. [2]
In vivo	Methods: Raji cells expressing luciferase were subcutaneously implanted into BALB/c nude mice. Following tumor formation, patients received oral gavage of Zanubrutinib (2.5 mg/kg) twice daily. Results: Zanubrutinib effectively inhibited tumor growth. [2] Methods: Eighteen male Sprague-Dawley rats were randomly divided into three groups and administered via gavage with 0.5% sodium carboxymethylcellulose solvent (control group), fluconazole (20 mg/kg), or itraconazole (20 mg/kg). Thirty minutes later, all rats received oral administration of Zanubrutinib (30 mg/kg). Results: Co-administration of the CYP3A4 inhibitors fluconazole and itraconazole significantly increased both the exposure (AUC) and peak concentration (Cmax) of Zanubrutinib. [3]
Synonyms	BGB-3111

Chemical Properties

Molecular Weight	471.55
Formula	C₂₇H₂₉N₅O₃
Cas No.	1691249-45-2
Smiles	NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1
Relative Density.	1.33 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 257.5 mg/mL (546.07 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.6 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1207 mL	10.6033 mL	21.2067 mL	106.0333 mL
5 mM	0.4241 mL	2.1207 mL	4.2413 mL	21.2067 mL
10 mM	0.2121 mL	1.0603 mL	2.1207 mL	10.6033 mL
20 mM	0.1060 mL	0.5302 mL	1.0603 mL	5.3017 mL
50 mM	0.0424 mL	0.2121 mL	0.4241 mL	2.1207 mL
100 mM	0.0212 mL	0.1060 mL	0.2121 mL	1.0603 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc